These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 31706158)

  • 21. A critical appraisal of the selegiline transdermal system for major depressive disorder.
    Bied AM; Kim J; Schwartz TL
    Expert Rev Clin Pharmacol; 2015; 8(6):673-81. PubMed ID: 26427518
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Augmentation of response and remission to serial intravenous subanesthetic ketamine in treatment resistant depression.
    Shiroma PR; Johns B; Kuskowski M; Wels J; Thuras P; Albott CS; Lim KO
    J Affect Disord; 2014 Feb; 155():123-9. PubMed ID: 24268616
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Serum BDNF as a peripheral biomarker of treatment-resistant depression and the rapid antidepressant response: A comparison of ketamine and ECT.
    Allen AP; Naughton M; Dowling J; Walsh A; Ismail F; Shorten G; Scott L; McLoughlin DM; Cryan JF; Dinan TG; Clarke G
    J Affect Disord; 2015 Nov; 186():306-11. PubMed ID: 26275358
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Continuation phase intravenous ketamine in adults with treatment-resistant depression.
    Vande Voort JL; Morgan RJ; Kung S; Rasmussen KG; Rico J; Palmer BA; Schak KM; Tye SJ; Ritter MJ; Frye MA; Bobo WV
    J Affect Disord; 2016 Dec; 206():300-304. PubMed ID: 27656788
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Esketamine nasal spray (Spravato) for treatment-resistant depression.
    Med Lett Drugs Ther; 2019 Apr; 61(1569):54-57. PubMed ID: 31169797
    [No Abstract]   [Full Text] [Related]  

  • 26. Intravenous ketamine for treatment-resistant major depressive disorder.
    Covvey JR; Crawford AN; Lowe DK
    Ann Pharmacother; 2012 Jan; 46(1):117-23. PubMed ID: 22190250
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Case of Tachyphylaxis After Long-Term Intravenous Racemic Ketamine for Treatment-Resistant Depression.
    Cavalcanti S; Lopez OA; Kung S; Vande Voort JL; Somers K; Frye MA; Singh B
    J Clin Psychopharmacol; 2024 May-Jun 01; 44(3):313-314. PubMed ID: 38597410
    [No Abstract]   [Full Text] [Related]  

  • 28. Combination of intravenous S-ketamine and oral tranylcypromine in treatment-resistant depression: A report of two cases.
    Bartova L; Vogl SE; Stamenkovic M; Praschak-Rieder N; Naderi-Heiden A; Kasper S; Willeit M
    Eur Neuropsychopharmacol; 2015 Nov; 25(11):2183-4. PubMed ID: 26302763
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Selegiline transdermal system for the treatment of major depressive disorder: an 8-week, double-blind, placebo-controlled, flexible-dose titration trial.
    Feiger AD; Rickels K; Rynn MA; Zimbroff DL; Robinson DS
    J Clin Psychiatry; 2006 Sep; 67(9):1354-61. PubMed ID: 17017821
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Short-term ketamine administration in treatment-resistant depression: focus on cardiovascular safety.
    Szarmach J; Cubała WJ; Włodarczyk A; Wiglusz MS
    Psychiatr Danub; 2019 Sep; 31(Suppl 3):585-590. PubMed ID: 31488795
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ineffectiveness of Repeated Intravenous Ketamine Infusions in Treatment-Resistant Depression After a Post-Ketamine Relapse: Time for a Rethink?
    López-Díaz Á; Fernández-González JL
    J Clin Psychopharmacol; 2018 Oct; 38(5):534-536. PubMed ID: 30106877
    [No Abstract]   [Full Text] [Related]  

  • 32. Efficacy and Safety of a Rapid Intravenous Injection of Ketamine 0.5 mg/kg in Treatment-Resistant Major Depression: An Open 4-Week Longitudinal Study.
    Vidal S; Gex-Fabry M; Bancila V; Michalopoulos G; Warrot D; Jermann F; Dayer A; Sterpenich V; Schwartz S; Vutskits L; Khan N; Aubry JM; Kosel M
    J Clin Psychopharmacol; 2018 Dec; 38(6):590-597. PubMed ID: 30346333
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of baseline anxious depression on initial and sustained antidepressant response to ketamine.
    Ionescu DF; Luckenbaugh DA; Niciu MJ; Richards EM; Slonena EE; Vande Voort JL; Brutsche NE; Zarate CA
    J Clin Psychiatry; 2014 Sep; 75(9):e932-8. PubMed ID: 25295436
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Repeated intranasal ketamine for treatment-resistant depression - the way to go? Results from a pilot randomised controlled trial.
    Gálvez V; Li A; Huggins C; Glue P; Martin D; Somogyi AA; Alonzo A; Rodgers A; Mitchell PB; Loo CK
    J Psychopharmacol; 2018 Apr; 32(4):397-407. PubMed ID: 29542371
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ketamine and Monoamine Oxidase Inhibitor Combination: Utility, Safety, Efficacy?
    Bottemanne H; Bonnard E; Claret A; Petit AC; Gaillard R; Fossati P
    J Clin Psychopharmacol; 2020; 40(6):636-638. PubMed ID: 33009225
    [No Abstract]   [Full Text] [Related]  

  • 36. Ketamine augmentation for outpatients with treatment-resistant depression: Preliminary evidence for two-step intravenous dose escalation.
    Cusin C; Ionescu DF; Pavone KJ; Akeju O; Cassano P; Taylor N; Eikermann M; Durham K; Swee MB; Chang T; Dording C; Soskin D; Kelley J; Mischoulon D; Brown EN; Fava M
    Aust N Z J Psychiatry; 2017 Jan; 51(1):55-64. PubMed ID: 26893373
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of Repeated Intravenous Ketamine in Treatment-Resistant Geriatric Depression: A Case Series.
    Bryant KA; Altinay M; Finnegan N; Cromer K; Dale RM
    J Clin Psychopharmacol; 2019; 39(2):158-161. PubMed ID: 30742589
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ketamine and Treatment-Resistant Depression.
    Lent JK; Arredondo A; Pugh MA; Austin PN
    AANA J; 2019 Oct; 87(5):411-419. PubMed ID: 31612847
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neurocognitive effects of six ketamine infusions and the association with antidepressant response in patients with unipolar and bipolar depression.
    Zhou Y; Zheng W; Liu W; Wang C; Zhan Y; Li H; Chen L; Li M; Ning Y
    J Psychopharmacol; 2018 Oct; 32(10):1118-1126. PubMed ID: 30260273
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Selegiline transdermal system in the prevention of relapse of major depressive disorder: a 52-week, double-blind, placebo-substitution, parallel-group clinical trial.
    Amsterdam JD; Bodkin JA
    J Clin Psychopharmacol; 2006 Dec; 26(6):579-86. PubMed ID: 17110814
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.